PPD and Lupus Therapeutics Collaborate to Support Lupus Clinical Research
Through the collaboration, PPD can provide enhanced protocol and trial optimization capabilities for its customers, drawing on LT’s scientific, operational and drug development expertise, as well as LT’s preferred investigators and Lupus Clinical Investigators Network (LuCIN) sites. In turn, in association with PPD, LT can provide patients with greater access to novel medicines and clinical care.
PPD’s immunology team has a dedicated group of experienced professionals with extensive lupus expertise, along with board-certified rheumatologists with industry and in-house experience in efficacy reviews, safety monitoring and site training for SLE trials. Through this collaboration, PPD has access to the more than 50 LuCIN research sites with over 200 affiliated investigators, who collectively see more than 20,000 active systemic lupus erythematosus (SLE) patients.
“Lupus Therapeutics is an exemplary organization to collaborate with because of its extensive lupus expertise,” said
Through this joint endeavor, PPD and its customers will benefit from the LT Patient Advocates for Lupus Studies (PALS) program, through which patient-to-patient interactions facilitate and improve clinical trial education and awareness for ongoing trial activities at participating LT centers.
“With the urgent need for new lupus treatments, we look forward to working with PPD on ways to accelerate and optimize the development of lupus clinical research,” said
Lupus is a chronic condition in which a person’s immune system attacks its own tissues and organs, causing inflammation that can damage any part of the body. Lupus is difficult to diagnose because its signs and symptoms can imitate a wide variety of other ailments.
Some of the key indications that Lupus Therapeutics addresses include SLE, lupus nephritis, chronic cutaneous (discoid) lupus, subacute cutaneous lupus, acute cutaneous lupus and central nervous system lupus.
PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our customers include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 24,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help customers bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppd.com.
About Lupus Therapeutics
Lupus Therapeutics is an affiliate of the
This news release contains forward-looking statements. These statements often include words such as “expect,” “believe,” “project,” “forecast,” “estimate,” “target” and other similar expressions. Although we believe these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our actual financial results, and therefore actual results might differ materially from those expressed in the forward-looking statements. Factors that might materially affect such forward-looking statements include, but are not limited to, the fragmented and highly competitive nature of the drug development services industry; changes in trends in the biopharmaceutical industry; our ability to keep pace with rapid technological changes that could make our services less competitive or obsolete; political, economic and/or regulatory influences and changes; and other factors disclosed under the “Risk Factors” section in our periodic reports filed with the